Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
Fate Therapeutics Inc. reported a Q3 net loss of $32.25 million, down from $47.68 million last year, amid restructuring efforts to streamline operations and extend its cash runway. Collaboration revenue fell to $1.74 million from $3.07 million. Despite losses, the company invested $25.84 million in R&D and focuses on strategic partnerships, notably with Ono Pharmaceutical, to advance its iPSC platform and clinical programs.
Fate Therapeutics Inc ( (FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Fate Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. In its latest earnings report, Fate Therapeutics highlighted a restructuring initiative aimed at streamlining operations and extending its cash runway, alongside ongoing collaborations to advance its product pipeline. The company reported a net loss of $32.25 million for the third quarter of 2025, compared to a $47.68 million loss in the same period last year, with collaboration revenue decreasing to $1.74 million from $3.07 million. Despite the financial losses, Fate Therapeutics continues to invest in research and development, with expenses totaling $25.84 million for the quarter. The company remains focused on its strategic partnerships, particularly with Ono Pharmaceutical Co., Ltd., which has been a significant contributor to its collaboration revenue. Looking ahead, Fate Therapeutics aims to leverage its iPSC platform and strategic collaborations to advance its clinical programs and achieve key milestones in the coming years.
